NCT01454479: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma |
|
|
| Unknown status | 1 | 24 | NA | Lapatinib and ixempra, Lapatinib, Ixempra | Hung-Hsueh Chou, GlaxoSmithKline, Bristol-Myers Squibb | Recurrent Endometrial Cancer | 04/13 | 04/14 | | |
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma |
|
|
| Active, not recruiting | 1 | 29 | US | Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery | National Cancer Institute (NCI) | Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma | 10/21 | 10/24 | | |
